pocketful logo
Nectar Lifescience Ltd logo

Nectar Lifescience Ltd

NSE: NECLIFE BSE: 532649

11.42

(0.62%)

Fri, 20 Mar 2026, 05:39 pm

Nectar Lifescience Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    213.49

  • Net Profit

    -113.68

  • P/B

    0.54

  • Sector P/E

    32.08

  • P/E

    0

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    12.90

  • RONW (Industry)

    12.30

  • ROE

    -11.23

  • ROCE

    -5.33

  • Debt/Equity

    0.60

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    36.75

  • Interest Cover

    -1.17

Analysis

all

thumbs up icon

Pros

  • Nectar Lifesciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Nectar Lifesciences is profitable, therefore cash runway is not a concern.
  • Nectar Lifesciences is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (33.8%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 2.2x debt.
thumbs up icon

Cons

  • Nectar Lifesciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
  • No need to calculate the sustainability of Nectar Lifesciences's dividends as it is not paying a notable one for India.
  • Nectar Lifesciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
  • Nectar Lifesciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Nectar Lifesciences's dividend is below the markets top 25% of dividend payers in India (3.08%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters44.9144.9144.5344.5344.53
FII0.520.620.811.650.73
DII5.820.090.190.160
Public48.7354.3754.4453.6554.72
Government0.020.020.020.020.02

Read More

Technical Analysis

RSI

26.21

MACD

-0.72

50 DMA

13.26

200 DMA

16.34

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic17.5315.1913.6912.8511.3510.518.17
Fibonacci15.1914.2913.7412.8511.9511.4010.51
Camarilla12.8412.6312.4112.8511.9911.7711.56

Pivots Level: Classic

R3

+4.68

17.53

R2

+2.34

15.19

R1

+0.85

13.69

12.85
12.85
Pivot Point
LTP: 10.96

S1

-1.49

11.35

S2

-2.34

10.51

S3

-4.68

8.17

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    11.25

  • 20-EMA

    11.73

  • 30-EMA

    12.27

  • 50-EMA

    13.23

  • 100-EMA

    14.71

  • 200-EMA

    17.32

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
23 Jan 2026board-meetingsQuarterly Results, Nine Months Results
03 Dec 2025buyback
24 Nov 2025buybackBuy Back of Shares24 Dec 2025
14 Nov 2025board-meetingsQuarterly Results
26 Aug 2025agm
07 Jul 2025egm
19 Aug 2024agm
13 Aug 2024agmAnnual General Meeting15 Sept 2024
14 Aug 2023agmAnnual General Meeting15 Sept 2023
26 May 2023agm

Read More

Peer Comparison

Nectar Lifescience Ltd logo

Nectar Lifescience Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Nectar Lifescience Ltd About

Nectar Lifescience is engaged in promoting education and employment enhancing vocational skills among women to help them in earning their livelihood.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1995

Headquarters

CEO

Sanjiv Goyal

Employees

Contact

Website icon

Website

http://www.neclife.com

Email icon

Email

cs@neclife.com

Phone icon

Phone

91-1762-308000

Location icon

Location

Village Saidpura, Tehsil Derabassi S A S Nagar, Mohali, Punjab, 140507

Read More

Nectar Lifescience Ltd Company History

YearHistory
2012
  • NecLife granted Certificate of Suitability for Cefuroxime Sodium in European Union
  • The Company recommended a 10% Final Dividend
  • Mr Harparkash Singh Gill was appointed as a Wholetime Director designated as President Operation and Director
2013
  • Mr Dinesh Dua was appointed as an Additional Director and Wholetime Director designated as Chief Executive Officer
2014
  • Mr Sanjiv Goyal received the Outstanding Entrepreneurship of the Year award from Asia Pacific Enterprise Awards
  • NecLife received European cGMP Approval for its Orals and Injectables Cephalsporins FDF Facility
2015
  • Nectar Lifesciences Ltd was honoured with the NECA 2015 Award.
2019
  • Nectar Biopharma launched a generic diabetes treatment drug in India.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
ANKITA VISHAL SHAHSell134952520.6504 Dec 2025
JAIDEEP SAMPATSell169574620.5404 Dec 2025
ANKITA VISHAL SHAHBuy134952521.0104 Dec 2025
MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITEDBuy150000020.9304 Dec 2025
IRAGE BROKING SERVICES LLPSell147903320.4704 Dec 2025
QE SECURITIES LLPBuy118023920.604 Dec 2025
IRAGE BROKING SERVICES LLPBuy80011220.4804 Dec 2025
RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITEDBuy150000020.8704 Dec 2025
QE SECURITIES LLPSell126693320.3604 Dec 2025
L7 HITECH PRIVATE LIMITEDBuy851002011 Jul 2025

Read More

Nectar Lifescience Ltd News

Nectar Lifesciences Postal Ballot Results Approved

Nectar Lifesciences shareholders approve director appointment of Sushil Kapoor and MOA amendments through postal ballot with over 99% support for key resolutions.

13 Mar 2026

companies

Nectar Lifesciences Signs INR 100 Crore Loan Deal

Nectar Lifesciences enters inter-corporate loan agreement with wholly owned subsidiary Avensis Exports for INR 100 crores at 12% interest rate with 10-year tenure for general corporate purposes.

12 Mar 2026

co actions results

Nectar Lifesciences wins litigation case dismissal

Mumbai court returns plaint filed by Sanjay Chemicals against Nectar Lifesciences citing lack of jurisdiction, disposing suit with no liability for the company.

07 Mar 2026

stocks

Nectar Lifesciences Approves INR 120 Crore Loan

Nectar Lifesciences board approves inter-corporate loan of up to INR 120 crores to wholly owned subsidiary Avensis Exports Private Limited following acquisition completion.

03 Mar 2026

co actions results

Nectar Lifesciences Acquires AEPL for ₹24.96 Lakh

Nectar Lifesciences board approves 100% acquisition of Avensis Exports Private Limited for ₹24.96 lakh to enter real estate business and changes RTA from KFin to Alankit.

02 Mar 2026

co actions results

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800